<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802658</url>
  </required_header>
  <id_info>
    <org_study_id>BRD/11/06-P</org_study_id>
    <secondary_id>2012-001778-27</secondary_id>
    <nct_id>NCT01802658</nct_id>
  </id_info>
  <brief_title>Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled (DBMZol)</brief_title>
  <acronym>DBMZol</acronym>
  <official_title>Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with lesion bone marrow are at risk of fracture by fragility bone. The median time
      to onset of fracture was 8.5 years. Fracture increases costs of care, dependency.

      Bone fragility is secondary to hormonal disorders and calcium phosphate, impaired excretion
      of neuropeptides, vasomotor symptoms associated with the asset that promote bone loss and
      architectural disorganization. These phenomena occur in the first weeks of development of
      spinal cord injury and predominate in the distal femur and proximal tibia. From the third
      year, the demineralization stabilizes, bone mass is estimated to be between 70 and 50% of the
      initial bone mass, the new equilibrium.

      No clinical evidence is predictive of fracture risk. A criteria surrogate must be used to
      assess this risk. There is an association between bone mineral density and fracture risk. The
      fracture threshold knee was evaluated to 0.87 g/cm2. Evaluation of bone mineral density in
      the distal femur is a predictor of fracture risk. Measure reliable and reproducible, easy to
      perform, it is a good element for monitoring the efficacy of anti-resorptive therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruiting Difficulty
  </why_stopped>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine DMO distal femur at 36 months</measure>
    <time_frame>october 2015</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of fractures of members lower in the first 36 months.</measure>
    <time_frame>october 2015</time_frame>
    <description>to determine incidence of fractures of members lower in the first 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to the EQ-5D questionnaire at baseline, M12, M24, M36.</measure>
    <time_frame>october 2015</time_frame>
    <description>To determine the EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DMO (g/cm2) at the distal femur, proximal femur, spine, total body M6, M12, M24, M36.</measure>
    <time_frame>october 2015</time_frame>
    <description>Determine the DMO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioassays: b CTX, PAO, PINP at M6, M12, M24, M36</measure>
    <time_frame>october 2015</time_frame>
    <description>to measure bioassays</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Further study of biological markers of bone resorption</measure>
    <time_frame>october 2015</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Study of bone architecture by QCT p</measure>
    <time_frame>october 2015</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Establishment of a bio-collection.</measure>
    <time_frame>october 2015</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Additional clinical follow-up study.</measure>
    <time_frame>october 2015</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Medico-economic analysis.</measure>
    <time_frame>october 2015</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Bone Demineralization Lesions in the Injured Marrow</condition>
  <arm_group>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times over two years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NACL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NACl 100 ml IV. 3 infusions. Administration 3 times over two years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.</description>
    <arm_group_label>Zoledronic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NA Cl</intervention_name>
    <description>NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.</description>
    <arm_group_label>NACL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Being diagnosed with a spinal cord injury less than 12 weeks of etiology stable,

          -  level of injury C5 L2,

          -  AIS grade A to D.

          -  Female or male between 18 and 45 years.

          -  No pregnancy.

          -  No osteoporosis.

          -  Good oral health.

          -  Good glomerular filtration.

          -  No cons-indication to Zoledronic Acid.

          -  No drugs affecting bone metabolism

        Exclusion Criteria:

          -  pregnancy.

          -  osteoporosis.

          -  cons-indication to Zoledronic Acid.

          -  drugs affecting bone metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Bouffard - Vercelli CAP Cerbère</name>
      <address>
        <city>Cerbère</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRMPR Les Herbiers</name>
      <address>
        <city>Les Herbiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Mutualiste Neurologique Propara</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Régional de Réadaptation Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital R. Poincaré</name>
      <address>
        <city>PAris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de l'Arche</name>
      <address>
        <city>Saint-Saturnin,</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Rangueil CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone marrow demineralization lesions,: efficacy and tolerability, zoledronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Demineralization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

